Summary

PRIMARY STUDY OBJECTIVES

- To evaluate the efficacy of the combination of clarithromycin (Biaxin®), lenalidomide
(Revlimid™), and dexamethasone (Decadron®) as an induction therapy for patients with
newly diagnosed multiple myeloma (MM).

- To evaluate the safety of the combination of clarithromycin, lenalidomide, and
dexamethasone as an induction therapy for patients with newly diagnosed MM.

SECONDARY STUDY OBJECTIVES

- To examine the role of clarithromycin on the pharmacokinetic properties of
dexamethasone and lenalidomide.

- To examine the angiogenesis profile in untreated patients and in patients receiving
induction therapy.